QIAGEN and Bio*One Capital collaborate on assay development centre

QIAGEN and Bio*One capital have entered a joint venture to establish Dx Assays Pte, Singapore’s first commercial entity which will focus upon the development of molecular diagnostics.

The assay development centre will be used for research into molecular diagnostics for infectious diseases.

Peer Schatz, chief executive officer of QIAGEN said of the development: "The in-depth expertise and talent pool in biomedical research makes Singapore an ideal location for a centre for assay development.

"This joint venture brings to QIAGEN further resources to contribute to our goal to further broaden our global portfolio of molecular testing solutions, to further accelerate our development speed and to expand our market and technology leadership in this fastest growing segment of diagnostics."

The new Singapore venture marks QIAGEN’s latest step in expanding its presence in Asia which is the company’s fastest growing sector.

The "state of the art centre" is expected to be open by early 2008.

Currently QIAGEN has 2,600 employees based in 30 centres around the world.